Funder: Novo Nordisk (home and overseas candidates eligible)Duration: 4 years (start October 2024)Supervisor: Professor James ElliottClosing date: 16 May 2024Stipend: EPSRC equivalent, £19327 per annum
During early-stage formulation and process development, scientists undergo extensive experimental screening campaigns and, although the tablet failure risk is reduced, there still exist risks that remain undetected and often cause issues during upscaling to production settings, leading to delays and at times undesired process changes. Being able to predict the compaction behaviour at different compression speeds, densities and compositions before formulations are transferred to large-scale production, will be a game changer in the tabletting field. Develop an experimental protocol to investigate the effect of the compression speed, tablet composition and powder characteristics on the tabletting performance.
Applications are made through the 'applicant portal' at .